GDF15 and sarcopenia: Age (< 70 years, p = 0.02), higher ASA score (p < 0.01), neoadjuvant chemotherapy (p = 0.03), and sarcopenia (p = 0.03) were associated with higher levels of GDF‐15 (Table 1).